Verastem reports 83% confirmed ORR in RAMP 205 dose level 1 for first-line metastatic pancreatic cancer

Verastem, Inc.

83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.
41 patients enrolled across 4 dose/schedule cohorts of avutometinib+defactinib+gemcitabine+nab-paclitaxel.
21 of 26 evaluable patients had reduction in target lesion sum of diameters as of May 14, 2024 cutoff.
12 patients experienced SAEs (11 grade ≥3); 2 discontinued due to treatment-emergent AEs.
Investor call on May 24, 2024 to discuss these data and rolling NDA submission in recurrent KRAS mutant LGSOC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.